KR20170052526A - 다발성 경화증에 대한 병용 치료 - Google Patents

다발성 경화증에 대한 병용 치료 Download PDF

Info

Publication number
KR20170052526A
KR20170052526A KR1020167027876A KR20167027876A KR20170052526A KR 20170052526 A KR20170052526 A KR 20170052526A KR 1020167027876 A KR1020167027876 A KR 1020167027876A KR 20167027876 A KR20167027876 A KR 20167027876A KR 20170052526 A KR20170052526 A KR 20170052526A
Authority
KR
South Korea
Prior art keywords
ser
thr
val
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020167027876A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 제드 탐
시어도어 예드녹
위에 리우
니콜라스 슈바브
하인츠 빈들
틸만 슈나이더-호헨도르프
Original Assignee
프로테나 바이오사이언시즈 리미티드
유니버시티 오브 뮌스터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로테나 바이오사이언시즈 리미티드, 유니버시티 오브 뮌스터 filed Critical 프로테나 바이오사이언시즈 리미티드
Publication of KR20170052526A publication Critical patent/KR20170052526A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167027876A 2014-03-13 2015-03-12 다발성 경화증에 대한 병용 치료 Abandoned KR20170052526A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461952835P 2014-03-13 2014-03-13
US61/952,835 2014-03-13
US201462023577P 2014-07-11 2014-07-11
US62/023,577 2014-07-11
PCT/IB2015/051785 WO2015136468A1 (en) 2014-03-13 2015-03-12 Combination treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
KR20170052526A true KR20170052526A (ko) 2017-05-12

Family

ID=52737375

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027876A Abandoned KR20170052526A (ko) 2014-03-13 2015-03-12 다발성 경화증에 대한 병용 치료

Country Status (6)

Country Link
US (1) US20170002077A1 (OSRAM)
EP (1) EP3116910A1 (OSRAM)
JP (2) JP2017510627A (OSRAM)
KR (1) KR20170052526A (OSRAM)
CA (1) CA2938945A1 (OSRAM)
WO (1) WO2015136468A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
EP3116911B8 (en) 2014-03-12 2019-10-23 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017134178A1 (en) * 2016-02-05 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Imaging method for predicting the onset of multiple sclerosis
WO2017149513A1 (en) * 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) * 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2019093481A1 (ja) * 2017-11-09 2019-05-16 北海道公立大学法人札幌医科大学 組織再生用医薬及びその製造方法
WO2021007533A1 (en) * 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP1017382B1 (en) 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
EP1001975A1 (en) 1997-07-31 2000-05-24 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
KR20010022406A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물
CA2290747A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
CN100369888C (zh) 1997-08-22 2008-02-20 霍夫曼-拉罗奇有限公司 芳酰基苯丙氨酸衍生物
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
ID28658A (id) 1998-04-16 2001-06-21 Texas Biotechnology Corp Senyawa yang menghambat pengikatan integrin pada reseptornya
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821406D0 (en) 1998-10-01 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
ATE490518T1 (de) 1999-02-05 2010-12-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zum wiederauffinden von texturbildern
ES2296625T3 (es) 1999-05-07 2008-05-01 Encysive Pharmaceuticals, Inc Derivados del acido carboxilico que inhiben el enlace de las integrinas con sus receptores.
AU6909300A (en) 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
US6689781B2 (en) 2000-07-21 2004-02-10 Elan Pharmaceuticals, Inc. Phenylalanine derivatives as alpha 4 integrin inhibitors
US7192931B2 (en) * 2000-10-12 2007-03-20 Neuren Pharmaceuticals Ltd. Treatment of demyelinating diseases
CA2438628A1 (en) * 2001-02-19 2002-08-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Artificial proteins with reduced immunogenicity
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CA2460149A1 (en) 2001-09-12 2003-03-27 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
JP2006516624A (ja) * 2003-01-24 2006-07-06 エラン ファーマシューティカルズ，インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
TR201820837T4 (tr) * 2007-06-14 2019-01-21 Biogen Ma Inc Natalizumab antikor formülasyonları.
US20130209463A1 (en) * 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
JP6305919B2 (ja) 2011-06-06 2018-04-04 プロセナ バイオサイエンシーズ リミテッド Ｍｃａｍアンタゴニスト及び治療の方法
TWI660972B (zh) * 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法

Also Published As

Publication number Publication date
JP2017510627A (ja) 2017-04-13
CA2938945A1 (en) 2015-09-17
WO2015136468A1 (en) 2015-09-17
JP2020100631A (ja) 2020-07-02
EP3116910A1 (en) 2017-01-18
US20170002077A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
TWI660972B (zh) 抗ｍｃａｍ抗體及相關使用方法
KR20170052526A (ko) 다발성 경화증에 대한 병용 치료
US20200079867A1 (en) Compositions and methods for enhancing the killing of target cells by nk cells
CN106554417B (zh) 抗ox40抗体和使用其的方法
TWI596112B (zh) 抗－ｃｘｃｒ３抗體
EP3606959A2 (en) Anti-icos agonist antibodies and uses thereof
JP6861301B2 (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
CA2836373A1 (en) Mcam antagonists and methods of treatment
JP2020502042A (ja) Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
KR20190038919A (ko) 항-nkg2d 항체로 크론병을 치료하는 방법
KR20240144440A (ko) 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체
CN120379647A (zh) 与tcr结合的多功能分子及其用途
KR20110128923A (ko) 인간 ｆａｓ에 대한 인간 항체 및 그의 용도
KR20250067121A (ko) Cnx 항원-결합 분자
TW202311293A (zh) 免疫療法之組合及其用途
JP2024535053A (ja) Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止
WO2022117569A1 (en) A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2023543835A (ja) 抗ｃｄ９４抗体及びその使用方法
TWI889320B (zh) 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
US20230151108A1 (en) Bispecific antibodies against cd9 and cd137
US20230151109A1 (en) Bispecific antibodies against cd9

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200311

Comment text: Request for Examination of Application

PC1902 Submission of document of abandonment before decision of registration